By Jake Siegel and Brian Finrow
Last week we announced a new collaboration with Aridis Pharmaceuticals to develop an intranasal passive vaccine to fight flu. We have written before about our efforts to use our unique manufacturing platform to develop edible antibody drugs for a wide range of infectious diseases. Now, we’re excited to explore a different delivery method for our biologic drugs: through the nose and upper airways.
The news comes not long after most of us in the northern hemisphere rolled up our sleeves for the annual flu shot. This offers a good opportunity to ‘think beyond the jab’ when it comes to vaccines.
